Lyramid Ltd and KineraLtd would themselves commercialise their IP including Advangen paying either as applicable for its Midkine for its Evolis range. The present "lifeline" would not be severed. Any other funding if required would be on commercial terms. However, the subsidiaries were never meant to bleed Cellmid. Good point Hobbit2233 I hope I've answered.
Ann: AGM Presentation by CEO, page-63
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.768M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.6¢ | $10.58K | 1.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3212402 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 2617059 | 3 |
View Market Depth
| Last trade - 12.49pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.6¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.6¢ | 0.6¢ | 0.6¢ | 214428 | ||
| Last updated 11.35am 17/06/2024 ? | |||||
| AN1 (ASX) Chart |
